- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07940829
A Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal Impairment
A Pharmacokinetic Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal Impairment
This study is a single-center, single-dose, open-label study designed to evaluate the pharmacokinetic (PK) profile of RSS0343 tablets in healthy participants and in participants with mild or moderate renal impairment.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Ruifang Guan
- Telefoonnummer: +86-518-82342973
- E-mail: ruifang.guan.rg1@hengrui.com
Studie Contact Back-up
- Naam: Hongda Lin
- Telefoonnummer: +86-518-82342973
- E-mail: hongda.lin@hengrui.com
Studie Locaties
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- The First Affiliated Hospital of Zhengzhou University
-
Hoofdonderzoeker:
- Youhong Hu
-
Hoofdonderzoeker:
- Zhanzheng Zhao
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Participants voluntarily sign the informed consent form (ICF), have a full understanding of the purpose and significance of this study, and are willing to comply with the study protocol.
- Males or females aged 18 to 65 years (both boundaries inclusive).
- Body weight ≥ 50 kg for males and ≥ 45 kg for females; body mass index (BMI) = weight (kg) / height² (m²), with BMI within the range of 19 to 28 kg/m² (both boundaries inclusive).
- The absolute value of estimated glomerular filtration rate (eGFR) shall be calculated using the Modification of Diet in Renal Disease (MDRD) equation modified for the Chinese population (for the equation and calculation method). Participants with mild renal impairment: absolute eGFR of 60-89 mL/min; participants with moderate renal impairment: absolute eGFR of 30-59 mL/min (boundary values inclusive); healthy participants: absolute eGFR ≥ 90 mL/min and < 130 mL/min.
- Male and female participants of reproductive / childbearing potential and their partners must have no plan for pregnancy or for sperm / oocyte donation within 6 months (female participants) or 3 months (male participants) after the last dose, and must be willing to use highly effective contraceptive measures. Female participants of childbearing potential must have a negative serum pregnancy test prior to the first dose and must not be breastfeeding.
- (For participants with renal impairment, the following additional inclusion criteria must also be met) The participant has been diagnosed with chronic (> 3 months) and stable renal injury (no acute exacerbation due to deterioration of renal function within 1 month prior to screening), and medical records or laboratory reports confirming the diagnosis of renal impairment for more than 3 months must be provided.
- (Participants with normal renal function) Physical examination, 12-lead electrocardiogram (12-ECG), vital signs, chest imaging, abdominal ultrasonography (color Doppler ultrasound) and laboratory tests at screening and baseline are normal, or abnormal without clinical significance.
Exclusion Criteria:
-
Those who smoked more than 5 cigarettes per day (or used an equivalent amount of other nicotine-containing products) within 3 months prior to screening, or who plan to use any tobacco products during the study.
-
Regular alcohol drinkers within 6 months prior to screening (i.e., daily alcohol intake exceeding 15 g for females and 25 g for males [5 g of alcohol is equivalent to 150 mL of beer, 50 mL of wine, or approximately 17 mL of low-alcohol liquor], on more than 2 occasions per week) who are unable to abstain from any alcohol-containing products during the study; or those with a positive alcohol breath test at baseline.
-
Those with a history of drug abuse, illicit drug use, or drug dependence (as determined by interview/medical history), or a positive urine drug screen at baseline.
-
Blood donation or blood loss of ≥ 200 mL in total within 1 month prior to dosing, or ≥ 400 mL in total within 3 months prior to dosing; receipt of a blood transfusion within 8 weeks prior to dosing; difficult venipuncture, or a physical condition that cannot tolerate intensive blood collection.
-
Positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV), syphilis antibody, or human immunodeficiency virus (HIV) antibody.
-
Suspected allergy / hypersensitivity to the investigational product or any of its components, or a history of severe allergy to any drug, food, toxin, or other exposure.
-
Any surgery within 3 months prior to screening, or incomplete recovery from surgery as judged by the investigator, or any surgery planned during the study period through 1 month after the end of the study.
-
Participants who refuse to abstain from any methylxanthine-containing beverages or foods (e.g., coffee, tea, cola, chocolate) from 48 hours prior to baseline until the end of the study; who refuse to abstain from any grapefruit-containing beverages or foods from 7 days prior to baseline until the end of the study; or who have special dietary requirements and are unable to comply with the standardized diet provided in the study.
-
Receipt of any live vaccine or live-attenuated vaccine within 1 month prior to screening, or a requirement for vaccination with a live vaccine during study participation (including within 30 days after the last dose of the investigational product).
-
Those who have participated in any clinical trials involving drugs or medical devices within three months prior to signing the informed consent form (or within five elimination half-lives of the studied drug, whichever is the longer period), excluding those who participated in other clinical trials but were not administered the drug due to screening failure.
Exclusion criteria for participants with renal dysfunction:
-
According to the judgment of the researchers, participants with renal dysfunction who are not suitable to participate in the study (such as those who have undergone kidney transplantation, those with urinary incontinence or anuria).
-
Those who, in the investigator's judgment, have experienced marked fluctuation or rapid deterioration of renal function within 2 weeks prior to dosing.
-
Those who have received renal replacement therapy (e.g., hemodialysis) within 3 months prior to screening, or who are expected to receive renal replacement therapy during the study.
-
Those with underlying diseases contributing to chronic kidney disease (e.g., diabetes mellitus, hypertension) that have been poorly controlled within 3 months prior to screening, as judged by the investigator.
-
Other than the primary renal disease itself, any history of serious disease, or any medical history and/or clinically significant abnormal clinical laboratory findings that, in the investigator's opinion, may affect the study results, including but not limited to a history of diseases of the circulatory, endocrine, nervous or digestive systems, or hematologic, immune, psychiatric or metabolic diseases.
-
Use of any prescription drugs, over-the-counter (OTC) drugs, Chinese patent medicines or dietary supplements, other than those used for the treatment of renal impairment and other concomitant diseases, within 2 weeks prior to administration of the study drug; or use of strong inhibitors or inducers of CYP3A4 and/or P-glycoprotein (P-gp) within 2 weeks prior to administration of the study drug.
Exclusion criteria for participants with normal renal function:
-
Previous severe primary diseases of important organs, including but not limited to gastrointestinal, respiratory, renal, liver, nervous, hematological, endocrine, tumor, immune, mental or cardiovascular and cerebrovascular diseases.
-
Use of any medication (including prescription drugs, over-the-counter drugs, herbal medicines, Chinese patent medicines, and dietary supplements) within 4 weeks prior to screening, or still within 5 half-lives of a drug at the time of screening (whichever is longer).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: RSS0343 Tablet Group
Administration of RSS0343 tablet. |
RSS0343 tablet, oral. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The maximum plasma concentration (Cmax)
Tijdsspanne: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
The area under the blood drug concentration-time curve from Time 0 to the last quantifiable concentration time (AUC0-t)
Tijdsspanne: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
The area under the blood drug concentration-time curve from Time 0 to the extrapolated infinite time (AUC0-inf)
Tijdsspanne: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to maximum plasma concentration (Tmax)
Tijdsspanne: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Terminal half-life (t1/2)
Tijdsspanne: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Apparent clearance (CL/F)
Tijdsspanne: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Apparent volume of distribution (Vz/F)
Tijdsspanne: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Cumulative amount of drug excreted unchanged in urine (Ae)
Tijdsspanne: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Fraction of the administered dose excreted unchanged in urine (Fe)
Tijdsspanne: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Renal clearance (CLr)
Tijdsspanne: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Plasma protein binding (PPB)
Tijdsspanne: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Incidence and severity of adverse events (AEs)
Tijdsspanne: Day 1 - Day 12.
|
Safety Parameter. |
Day 1 - Day 12.
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- RSS0343-105
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .